Febuxostat for hyperuricemia: Experience with patients on chronic hemodialysis treatment

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 149-150

  Horikoshi, Ryoko ^a,b   Akimoto, Tetsu ^b   Inoue, Makoto ^a,b   Morishita, Yoshiyuki ^b   Kusano, Eiji ^b  

^a IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic kidney disease; Febuxostat; Hemodialysis; Uric acid

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID;

ABSENCE OF SIDE EFFECTS; AGED; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; HYPERURICEMIA; LETTER; LOW DRUG DOSE; MALE; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DRUG MONITORING; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; RENAL DIALYSIS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84874107233     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0763-7     Document Type: Letter

References (5)

1. Hosoya T, Ono I. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol. 2011;17(4 suppl 2):S27-34.
2. Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018-29.
3. El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med. 2010;77:919-28.
4. Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL, Marshall MR, Kleophas W, Levin NW, Sen A, Robinson BM, Saran R. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6:2470-7.
5. Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266-72.